Sen-Jam Pharmaceutical

Early Birds Get Seriously Great Worms

Dear Investors, Colleagues and Friends,

They say the early bird gets the worm. The same could hold true for our investors, as there is still a lot of upside potential for Sen-Jam Pharmaceutical.

Why is today a great entry point for becoming a SJP investor? Not only do you benefit from all of Sen-Jam’s assets underdevelopment, but for a limited time, we are offering a dividend (Fractional Royalty Right) based on our portfolio of 21 patents for inhibiting the adverse effects of alcohol (SJP-001). Given our 10-year licensing projections for SJP-001 of $878,960,286*, an investment now will drive the value of Sen-Jam higher and has the potential to return the following dividend over the next 10 years:

  • $10,000 - $329,610 or $32,961/year for 10 years
  • $25,000 - $824,025 or $82,403/year for 10 years
  • $50,000 - $1,648,051 or $164,805/year for 10 years
  • $100,000 - $3,296,100 or $329,610/year for 10 years

Together, we can stamp out inflammation and its impact on humanity and wellbeing. Join us by investing for the first time or investing again as many have here on Join this limited-time offer to have your cake and eat it, too.

Let’s do this…


* This is only a projection and the actual licensing revenue may differ.